Precipitated withdrawal following codeine administration is dependent on CYP genotype.

[1]  A. Somogyi,et al.  The Relationship Between Mood State and Plasma Methadone Concentration in Maintenance Patients , 2001, Journal of clinical psychopharmacology.

[2]  R. Tyndale,et al.  Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. , 2000, Journal of clinical psychopharmacology.

[3]  R. Tyndale,et al.  Cytochrome P450 2D6 and treatment of codeine dependence. , 2000, Journal of clinical psychopharmacology.

[4]  R. Tyndale,et al.  Mimicking Gene Defects to Treat Drug Dependence , 2000, Annals of the New York Academy of Sciences.

[5]  B. Sproule,et al.  Characteristics of dependent and nondependent regular users of codeine. , 1999, Journal of clinical psychopharmacology.

[6]  A. Somogyi,et al.  Steady‐state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration‐effect relationships , 1999, Clinical pharmacology and therapeutics.

[7]  G. Tucker,et al.  Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. , 1999, Pharmacogenetics.

[8]  R. Calvo,et al.  Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[9]  F. Gonzalez,et al.  Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. , 1998, Pharmacogenetics.

[10]  A. Malhotra,et al.  Abuse of codeine-containing cough syrups: a report from India. , 1997, Addiction.

[11]  A. Somogyi,et al.  The effect of old age on the disposition and antinociceptive response of morphine and morphine-6β-glucuronide in the rat , 1997, Pain.

[12]  A. Somogyi,et al.  CONCENTRATION‐EFFECT RELATIONSHIPS OF MORPHINE AND MORPHINE‐6β‐GLUCURONIDE IN THE RAT , 1997, Clinical and experimental pharmacology & physiology.

[13]  U. Hofmann,et al.  Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype , 1997, Clinical pharmacology and therapeutics.

[14]  A. Somogyi,et al.  The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. , 1996, Drug metabolism reviews.

[15]  S. Sindrup,et al.  The pharmacogenetics of codeine hypoalgesia. , 1995, Pharmacogenetics.

[16]  A. Somogyi,et al.  The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. , 1994, The Journal of pharmacology and experimental therapeutics.

[17]  M. Eichelbaum,et al.  Thebaine O-demethylation to oripavine: genetic differences between two rat strains. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  M. Eichelbaum,et al.  Codeine O-demethylation: rat strain differences and the effects of inhibitors. , 1991, Biochemical pharmacology.

[19]  A. Somogyi,et al.  Mu receptor binding of some commonly used opioids and their metabolites. , 1991, Life sciences.

[20]  A. Somogyi,et al.  Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. , 1990, Life sciences.

[21]  A. Somogyi,et al.  Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high-performance liquid chromatography with fluorescence detection. , 1989, Journal of chromatography.

[22]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[23]  L. Ahtee,et al.  Comparative studies on the dependence liability of morphine hydrochloride, codeine phosphate and two novel antitussive compounds vadocaine hydrochloride and N-(2',4'-dimethyl-6'-methoxyphenyl)-4-(diethylamine) butanamide hydrochloride in mice. , 1988, Arzneimittel-Forschung.

[24]  C. Kozak,et al.  Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. , 1987, DNA.

[25]  W. Colburn,et al.  Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain , 1987, Clinical pharmacology and therapeutics.

[26]  M. Rubenfield,et al.  Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[27]  F. Guengerich,et al.  Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. , 1984, Biochemistry.

[28]  S. Yanaura,et al.  Induction of physical dependence on codeine in the rat by drug-admixed food ingestion. , 1984, Japanese journal of pharmacology.

[29]  J. Idle,et al.  Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains , 1981, The Journal of pharmacy and pharmacology.

[30]  S. Snyder,et al.  Opiate Receptor: Demonstration in Nervous Tissue , 1973, Science.